#1 Clinical Trials Search in Europe

Danicamtiv

Danicamtiv, also known as BMS-986434 or MYK-491, is a novel drug currently being studied in clinical trials for various heart conditions, including dilated cardiomyopathy and heart failure with reduced ejection fraction. This article provides an overview of the ongoing research, potential benefits, and safety considerations of Danicamtiv based on recent clinical trials.

Table of Contents

What is Danicamtiv?

Danicamtiv is a new drug being studied for its potential to treat certain heart conditions. It’s also known by other names, including MYK-491 and BMS-986434[1]. This medication is still in the research phase, which means it’s not yet available for general use and is being carefully tested to understand how it works and how safe it is.

How Does Danicamtiv Work?

Danicamtiv is classified as a myosin activator[1]. To understand what this means, let’s break it down:

  • Myosin: This is a protein in your heart muscle cells that helps your heart contract and pump blood.
  • Activator: This means the drug helps to increase or improve the activity of myosin.

By activating myosin, Danicamtiv aims to improve the heart’s ability to contract and pump blood more effectively. This could potentially help people whose hearts are not working as well as they should.

What Conditions Does Danicamtiv Treat?

Danicamtiv is being studied primarily for the treatment of Primary Familial Dilated Cardiomyopathy (DCM)[1]. This is a heart condition where:

  • Primary means it’s the main problem, not caused by another condition.
  • Familial indicates it can run in families.
  • Dilated Cardiomyopathy refers to a condition where the heart becomes enlarged and cannot pump blood effectively.

Researchers are particularly interested in how Danicamtiv might help people with DCM caused by specific genetic variants, especially in genes called MYH7 and TTN[1].

Additionally, Danicamtiv is being studied in patients with Heart Failure with Reduced Ejection Fraction (HFrEF)[3]. This is a condition where the heart muscle doesn’t pump blood as well as it should, leading to various symptoms and complications.

Current Research on Danicamtiv

Several clinical trials are currently underway to study different aspects of Danicamtiv:

  1. Safety and Efficacy Study: A Phase 2a study is examining how safe Danicamtiv is and how well it works in patients with primary DCM[1].
  2. Formulation and Food Effect Study: Researchers are looking at how different formulations of the drug are absorbed by the body and how food affects its levels in the body[2].
  3. Drug Interaction Studies: Scientists are investigating how Danicamtiv interacts with other medications like midazolam, itraconazole, and diltiazem[3][5].
  4. Ethnic Comparison Study: A study is comparing how the drug affects Japanese and Caucasian participants to see if there are any differences[4].

Safety and Side Effects

As Danicamtiv is still in the research phase, its full safety profile is not yet known. However, the clinical trials are closely monitoring for any side effects or safety concerns. Some of the things being watched include:

  • Adverse events (any unexpected medical problems that happen during the study)
  • Changes in vital signs
  • Abnormalities in electrocardiogram (ECG) readings
  • Changes in physical examination findings
  • Abnormalities in laboratory test results

These are being monitored in both short-term studies (up to 22 days) and longer-term studies (up to 96 weeks)[1][2][3][4][5].

Drug Interactions

Researchers are studying how Danicamtiv interacts with other medications. This is important because many patients with heart conditions often take multiple medications. Some specific interactions being studied include:

  • Midazolam: A common sedative medication[3].
  • Itraconazole: An antifungal medication[5].
  • Diltiazem: A medication used to treat high blood pressure and certain heart rhythm problems[5].

These studies will help doctors understand how to safely prescribe Danicamtiv alongside other medications in the future, if it’s approved for use.

Aspect Details
Drug Name Danicamtiv (also known as BMS-986434, MYK-491)
Drug Type Myosin activator
Conditions Studied Primary Dilated Cardiomyopathy (DCM), Heart Failure with Reduced Ejection Fraction (HFrEF)
Trial Phases Phase 1 and Phase 2a
Primary Outcomes Safety, tolerability, pharmacokinetics, adverse events
Secondary Outcomes Changes in heart function parameters, drug interactions
Study Populations Patients with specific heart conditions, healthy volunteers (including Japanese and Caucasian participants)
Key Measurements Echocardiography parameters, drug concentration in plasma, vital signs, ECG

FAQ

  • What is Danicamtiv and how does it work? Danicamtiv is a myosin activator, which means it helps improve heart muscle contraction. It's being studied as a potential treatment for certain heart conditions, particularly those affecting the heart's ability to pump blood effectively.
  • What conditions is Danicamtiv being studied for? Danicamtiv is being investigated for primary dilated cardiomyopathy (DCM), including cases caused by genetic variants, and heart failure with reduced ejection fraction (HFrEF).
  • Are there any side effects associated with Danicamtiv? As with any drug in clinical trials, researchers are closely monitoring for potential side effects. The trials are assessing the frequency and severity of adverse events, as well as any abnormalities in vital signs, physical examinations, ECGs, and laboratory tests.
  • How is Danicamtiv administered? The specific dosing of Danicamtiv varies depending on the trial. In some studies, it's given as a single dose, while in others, it may be administered over a period of time. The exact method of administration is determined by the researchers for each specific trial.
  • Can anyone participate in these clinical trials? Participation criteria vary for each trial. Some studies involve patients with specific heart conditions, while others are conducted with healthy volunteers. Each trial has its own set of inclusion and exclusion criteria to ensure the safety of participants and the validity of the research.

Ongoing Clinical Trials on Danicamtiv

  • A Study of Danicamtiv for Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy to Test if it Improves Heart Function and Exercise Ability

    Recruiting

    4 1
    Investigated drugs:
    Belgium Denmark France Hungary Italy The Netherlands +3

  • Study on Danicamtiv for Patients with Primary Dilated Cardiomyopathy Due to MYH7 or TTN Gene Variants

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Spain

Glossary

  • Dilated Cardiomyopathy (DCM): A condition where the heart's main pumping chamber (left ventricle) becomes enlarged and weakened, reducing its ability to pump blood effectively.
  • Heart Failure with Reduced Ejection Fraction (HFrEF): A type of heart failure where the heart muscle doesn't contract effectively, and thus less oxygen-rich blood is pumped out to the body.
  • Myosin Activator: A type of drug that enhances the function of myosin, a protein in heart muscle cells that is crucial for contraction.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Echocardiography: An imaging test that uses sound waves to create pictures of the heart, allowing doctors to see its size, shape, and function.
  • Ejection Fraction: A measurement of how much blood the left ventricle pumps out with each contraction.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, or causes significant disability.

References

  1. https://clinicaltrials.gov/study/NCT04572893
  2. https://clinicaltrials.gov/study/NCT06027437
  3. https://clinicaltrials.gov/study/NCT05952089
  4. https://clinicaltrials.gov/study/NCT05806359
  5. https://clinicaltrials.gov/study/NCT05162222